Ultragenyx Pharmaceutical Inc, Novato, CA, USA.
Tianjin Happy Life Technology Co., Ltd, Beijing, China.
Curr Med Res Opin. 2024 Nov;40(11):1893-1906. doi: 10.1080/03007995.2024.2405124. Epub 2024 Sep 26.
Long-chain fatty acid oxidation disorders (LC-FAOD) are a group of rare genetic inborn errors of metabolism. Clinical manifestations may result in frequent healthcare visits, hospitalizations, and early death. This retrospective cohort study assessed manifestations, healthcare resource use (HRU), direct medical costs, and the impact of COVID-19 on HRU among patients with LC-FAOD.
The IQVIA PharMetrics Plus database was searched for pediatric (0-17 years) and adult (≥18 years) patients with confirmed LC-FAOD (ICD-10-CM Diagnosis Code E71.310) and ≥12 months continuous enrollment (CE) between January 2016-February 2020. A non-LC-FAOD general population cohort was randomly selected and matched using 1:20 exact matching on age, gender, payer type, and CE start year. Manifestations were identified via ICD-10 diagnosis codes (any billing position). Overall HRU and attributable costs were stratified by care setting. Pre-COVID-19 (March 2019-February 2020) and during COVID-19 (March 2020-February 2021) HRU was assessed among a subgroup of patients and the general population. Outcomes were evaluated among children and adults, respectively.
423 patients with LC-FAOD (47% female; 79.7% children) were included. The mean enrollment duration was 2.6 ± 1.2 years. 22.6% of children with LC-FAOD had at least one major clinical event (MCE), consisting of rhabdomyolysis (10.1%), hypoglycemia (9.8%), or cardiomyopathy (8.6%) versus 1.5% overall occurrence in the general population. Adults with LC-FAOD had a higher incidence of MCEs (37.2%) than children with LC-FAOD. Annualized all-cause HRU in all care settings and mean total annualized medical costs (children: $17,082 vs $4144; adults: $43,602 vs $3949) were higher in patients with LC-FAOD versus the general population. Patients with LC-FAOD had substantially fewer healthcare visits during COVID-19 across care settings than during the pre-COVID-19 period.
LC-FAOD impart a high burden on patients. Extended hospital stays and increased outpatient management were especially pronounced for adults and for patients with ≥1 MCE, resulting in substantially higher medical costs than the general population.
长链脂肪酸氧化障碍(LC-FAOD)是一组罕见的遗传性代谢缺陷。临床表现可能导致频繁的医疗就诊、住院和早逝。本回顾性队列研究评估了 LC-FAOD 患者的表现、医疗资源利用(HRU)、直接医疗成本以及 COVID-19 对 HRU 的影响。
在 2016 年 1 月至 2020 年 2 月期间,使用 IQVIA PharMetrics Plus 数据库搜索了患有 LC-FAOD(ICD-10-CM 诊断代码 E71.310)并至少有 12 个月连续入组(CE)的儿科(0-17 岁)和成人(≥18 岁)患者(ICD-10 诊断代码(任何计费位置))。总体 HRU 和归因成本按护理环境进行分层。在 COVID-19 期间(2020 年 3 月至 2021 年 2 月)评估了亚组患者和普通人群的 COVID-19 之前(2019 年 3 月至 2020 年 2 月)和 COVID-19 期间(2020 年 3 月至 2021 年 2 月)的 HRU。结果分别在儿童和成人中进行了评估。
共纳入 423 例 LC-FAOD 患者(47%为女性;79.7%为儿童)。平均入组时间为 2.6±1.2 年。22.6%的儿童 LC-FAOD 患者至少发生了一次重大临床事件(MCE),包括横纹肌溶解症(10.1%)、低血糖症(9.8%)或心肌病(8.6%),而普通人群的总发生率为 1.5%。与儿童 LC-FAOD 患者相比,成人 LC-FAOD 患者的 MCE 发生率更高(37.2%)。在所有护理环境中,所有病因的年化 HRU 和年化医疗总费用(儿童:$17082 与 $4144;成人:$43602 与 $3949)在 LC-FAOD 患者中均高于普通人群。与 COVID-19 之前相比,COVID-19 期间 LC-FAOD 患者在所有护理环境中的就诊次数均明显减少。
LC-FAOD 给患者带来了沉重的负担。成人和发生≥1 次 MCE 的患者的住院时间延长和门诊管理增加尤其明显,导致医疗费用明显高于普通人群。